Introduction {#sec1_1}
============

Carcinoma ex pleomorphic adenoma (CXPA) is a rare histologic subtype of submandibular gland and lacrimal gland cancer \[[@B1]\]. This tumor predominantly affects the parotid gland and accounts for 11% of salivary gland malignancies \[[@B2]\]. On the other hand, only a few primary lacrimal CXPA have been reported \[[@B3]\].

Currently, there is no standard treatment for metastatic CXPA, although some case reports have explored the role of targeted agents in chemotherapy \[[@B4], [@B5]\]. A histopathologic analysis of 31 cases of CXPA showed that some of these tumors overexpress human epidermal growth factor receptor-2 (HER2) \[[@B6]\]. CXPA in the minimally invasive phase has an excellent prognosis regardless of histological subtype or molecular factor \[[@B7]\]. However, advanced or metastatic CXPA have a poor prognosis, and HER2 overexpression is significantly associated with a worse prognosis in advanced CXPA \[[@B6]\]. These data suggest a potential utility for HER2-targeted chemotherapy against this subtype of tumor.

We report here two cases of metastatic CXPA of the lacrimal gland and submandibular gland, respectively, that were treated with trastuzumab (Tmab; an anti HER2 monoclonal antibody) combined with nabPTX chemotherapy (IRB approved) with rapid and significant responses.

Case Report 1 {#sec1_2}
=============

A 66-year-old male noticed exacerbation of right exophthalmos and diplopia a few months before his initial visit to our institution. Head computed tomography (CT) and magnetic resonance imaging (MRI) revealed a tumor in the right orbit. Tumorectomy of the right lacrimal gland with enucleation was performed. Histologically, the tumor consisted of broad hyalinized stroma with nests of tumor cells, low atypical ductal structure background and a pleomorphic adenoma-component (Fig. [1A, B](#F1){ref-type="fig"}). The resected tumor showed strong positivity for HER2 immunostaining (score 3+, Fig. [1C](#F1){ref-type="fig"}). Consequently, the patient was diagnosed with HER2-positive CXPA of the lacrimal grand. After surgery, positron emission tomography (PET)-CT was performed, which revealed multiple bone and lymph node metastatic lesions. Then, combination chemotherapy with Tmab (8 mg/kg dose loading, followed by 6 mg/kg every three weeks) and nab-paclitaxel (nabPTX; 220 mg/m^2^ every three weeks) was initiated. A rapid partial response was confirmed after only two treatment cycles without any severe adverse effects. After seven cycles, PET-CT revealed no evidence of residual tumor and CR was achieved (Fig. [2](#F2){ref-type="fig"}). The patient was maintained with trastuzumab monotherapy without disease recurrence. After 6 months of Tmab maintenance therapy, we decided to terminate the Tmab administration. He continues to be disease-free more than two years after the initiation of Tmab and nabPTX combination therapy.

Case Report 2 {#sec1_3}
=============

A 67-year-old female noticed enlargement of a right submandibular nodule, which had existed for more than 30 years, and visited a local hospital. Head and neck CT and MRI revealed an irregularly shaped, approximately 7 × 5 cm tumor in her right submandibular gland. A total right submandibular-glandectomy was performed. The tumor consisted of a salivary duct carcinoma (SDC) component with low atypical ductal structures and hyalinized stroma. On the basis of the above information, she was diagnosed as CXPA with an SDC component of the right submandibular gland. The resected tumor showed strong positivity for HER2 (score 3+). Thereafter, combination chemotherapy with Tmab and nabPTX was initiated. A rapid partial response was confirmed after only one treatment cycle, without any severe toxicity. The best overall response (PR, −76%) was achieved after eight cycles of treatment (Fig. [3](#F3){ref-type="fig"}). However, she suffered from CTCAE(Common Terminology Criteria for Adverse Events v4.0) grade 2 peripheral neutropenia, induced by the eight courses of nabPTX treatment. We decided then to exclude nabPTX and continue only with Tmab as a maintenance therapy. We continued the HER2-based chemotherapy for more than a year, and performed a partial lung resection to remove the only remaining lung tumor. The patient has remained disease-free without recurrence for more than two years after initiation of nabPTX and Tmab combination therapy.

Discussion {#sec1_4}
==========

Salivary gland cancers and lacrimal gland cancers comprise a heterogenous group of rare tumors. Especially, CXPA is a rare histologic subtype of these head and neck tumors. A certain population of CXPA is known to overexpress HER2 and could potentially benefit from the treatment with HER2-targeted agents \[[@B6]\].

Tmab was one of the first molecular-targeted drugs to be developed and was originally introduced for the treatment of HER2-positive metastatic breast cancer \[[@B8]\]. Based on the findings accumulated from the treatment of breast cancer, Tmab is now considered a key drug for treating HER2-positive malignancies.

In a phase II trial of Tmab monotherapy in fourteen patients with advanced HER2-positive salivary gland carcinomas, only one partial response (7.1%) was achieved \[[@B9]\]. However, a handful of case series have demonstrated dramatic responses to Tmab-based combination chemotherapy regimens against HER2-positive SDC, including CXPA, suggesting the potential utility of Tmab combination therapy (Table [1](#T1){ref-type="table"}) \[[@B4], [@B5], [@B10], [@B11]\].

As the anti-cancer agent to combine with Tmab, we selected nabPTX, an albumin-bound form of paclitaxel, which was solvent-free and designed to improve the therapeutic index of paclitaxel \[[@B12]\]. Taxanes are among the most widely used chemotherapy agents in the treatment of malignant tumors, including breast, lung, and gastric cancer \[[@B13], [@B14], [@B15]\]. In addition, recent studies have shown clinical efficacy of taxane-trastuzumab combination regimens in HER2-positive cancer \[[@B8]\]. Therefore, we selected nabPTX as the partner in Tmab combination therapy.

In the present study, we have presented two cases of HER2-positive metastatic CXPA derived from the salivary gland and lacrimal gland, respectively. Combination treatment with Tmab and nabPTX demonstrated a promising anti-tumor effect without any severe adverse effects.

In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of this tumor, we believe that our case report suggests a potential utility of Tmab-based chemotherapy for HER2-positive CXPA.
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![Histopathological Findings of the Tumor Derived from Case 1. (**A**) Carcinomatous component (×100 magnification). (**B**) Low atypical ductal structure (arrow) and hyalinized stroma (asterisk), hematoxylin and eosin staining (×200 magnification). (**C**) Immunohistochemical analysis of HER2 staining of the tumor (×200 magnification). The tumor cells were strongly positive for HER2 (Score 3+).](cro-0011-0835-g01){#F1}

![Clinical Course of Case 1. (**A**) PET-CT scan revealed local recurrence, multiple bone and lymph node metastases (Baseline). (**B**) A complete response was achieved after seven cycles of Tmab + nabPTX treatment.](cro-0011-0835-g02){#F2}

![Clinical Course of Case 2. (**A**) Thoracic CT scan revealed multiple pulmonary and lymph node metastases (Baseline). (**B**) A partial response (--76%) was observed after eight cycles of Tmab + nabPTX treatment.](cro-0011-0835-g03){#F3}

###### 

Review of Literature --Tmab Combination Therapy for CXPA or SDC

  Author                                Patients, *n*   Pathology    Regimen                Response
  ------------------------------------- --------------- ------------ ---------------------- ---------------
  Hadda et al: Oral Oncol 2003          14              SDC          Tmab monotherapy       CR0, PR1 (7%)
  Prat et al: Head Neck 2008            1               SDC          CBDCA/PTX+Tmab         CR
  Nashed et al: J Laryngol Otol 2009    1               SDC (CXPA)   DTX+Tmab               CR
  Sharon et al: Head Neck Oncol 2010    1               CXPA         Capecitabine+Tmab      CR
  Kaidar-Person et al: Med Oncol 2012   1               SDC          CBDCA/PTX+Tmab         CR
  Kadowaki et al: Case Rep Oncol 2013   1               SDC (CXPA)   PTX+Tmab               CR
  Thorpe et al: Head Neck 2017          2               CXPA, SDC    PTX+Tmab, chemo+Tmab   CR1, PR1
  Hassanieh et al: Front Oncol 2018     1               CXPA         TDM1                   
                                                                                            
  Our Cases                             2               CXPA 2       nabPTX+Tmab            CR1, PR1

CR, complete response; PR, partial response; CBDCA, carboplatin; PTX, paclitaxel; DTX, docetaxel; TDM1, Trastuzumab Emtansine.
